NCT04466891 2025-09-15
HERIZON-BTC-01
Jazz Pharmaceuticals
Phase 2 Completed
Clinical Trials
46 trialsNCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05239169 2025-05-01
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT03201458 2024-04-05
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03260712 2023-11-03
Pembrolizumab in Biliary Tract Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT03833661 2023-10-25
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
EMD Serono
Phase 2 Completed
NCT04072445 2023-08-09
Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Mayo Clinic
Phase 2 Completed
NCT03278106 2023-06-28
TAS-102 in Treating Advanced Biliary Tract Cancers
Mayo Clinic
Phase 2 Completed
NCT02520141 2023-06-15
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03473574 2023-06-15
IMMUCHEC
AIO-Studien-gGmbH
Phase 2 Completed
NCT02392637 2022-02-02
Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03111732 2021-12-03
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02115542 2021-10-12
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02631590 2021-08-04
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03231176 2020-11-19
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer
ASLAN Pharmaceuticals
Phase 2 Completed
NCT02053376 2019-01-30
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
University of Pittsburgh
Phase 2 Completed
NCT00101036 2018-04-20
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00789958 2018-04-09
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
SWOG Cancer Research Network
Phase 2 Completed
NCT00033540 2017-09-12
S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
SWOG Cancer Research Network
Phase 2 Completed
NCT02042443 2017-09-12
S1310
National Cancer Institute (NCI)
Phase 2 Completed
NCT01007552 2017-03-29
A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts
Roswell Park Cancer Institute
Phase 2 Completed
NCT01572324 2017-01-04
Study of Hepatic Arterial Infusion to Treat Biliary Tract Carcinomas
Peking University
Phase 2 Completed
NCT00009893 2016-12-07
Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00753675 2016-10-10
VANGOGH
Sanofi
Phase 2 Completed
NCT01308840 2016-08-17
UGIH09067
University of Rochester
Phase 2 Completed
NCT00003276 2016-07-06
Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01425879 2016-06-17
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00919061 2016-02-03
Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00075504 2015-09-28
Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01093222 2015-06-30
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00660699 2015-05-27
A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers
Washington University School of Medicine
Phase 2 Completed
NCT00107536 2015-04-29
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00356889 2014-05-28
Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003557 2014-03-06
Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer
University of Chicago
Phase 2 Completed
NCT00096083 2013-10-23
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Delcath Systems Inc.
Phase 2 Completed
NCT00660140 2013-08-13
Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer
Washington University School of Medicine
Phase 2 Completed
NCT00033462 2013-06-04
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003923 2013-03-04
Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00238212 2013-01-14
S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00338988 2012-08-01
Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00073905 2012-06-05
Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer
Swiss Cancer Institute
Phase 2 Completed
NCT00005938 2012-05-16
DX-8951f in Treating Patients With Biliary Cancer
Daiichi Sankyo
Phase 2 Completed
NCT01320241 2012-04-02
Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture
Southeast University, China
Phase 2 Completed
NCT00084942 2012-01-12
Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder
Roswell Park Cancer Institute
Phase 2 Completed
NCT00350753 2009-07-15
Avastin and Tarceva for Upper Gastrointestinal Cancers
Rigshospitalet, Denmark
Phase 2 Completed
NCT00123825 2007-12-21
Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer
Dana-Farber Cancer Institute
Phase 2 Completed